Crumley Roberts Investigates the Link between Actos® and Bladder Cancer
Greensboro, N.C. – January 13, 2012 – Crumley Roberts began contacting clients this week whose case history may have indicated they took the drug Actos®(pioglitazone) or one of its derivatives.
Recently, a European study raised concern about the use of the diabetes drug Actos ® and the development of bladder cancer. The Food and Drug Administration has issued a warning that the use of Actos for one year or longer may cause bladder cancer in some users. Actos®is the brand name for the drug “pioglitazone.” Pioglitazone, combined with the common diabetes drug metformin, has been sold as Actoplus Met ®. Pioglitazone, combined with glimepiride, has been marketed under the name Duetact ®.
Current studies have NOT shown any connection between metformin or glimepiride used alone or in other combinations with bladder cancer. To learn more about this warning, please visit our website.
Founded in 1989, Crumley Roberts, LLP, represents individuals with personal injury, workers' compensationand Social Security disability claims. The firm operates from 14 offices in North Carolina and South Carolina. To learn more about the firm, or its community relations activities, visit www.crumleyroberts.comor stay connected on Twitter, Facebookor LinkedIn.Free Initial Consultation